Literature DB >> 36094183

Pharmacokinetics of Ascending Doses of Praziquantel in Adults Infected with Opisthorchis felineus in Western Siberia, Russian Federation.

Alexandra Probst1,2, Daniela Hofmann1,2, Olga S Fedorova3, Sofia V Mazeina3, Tatiana S Sokolova3, Ekaterina Golovach3, Jennifer Keiser1,2.   

Abstract

Opisthorchiasis due to the liver fluke Opisthorchis felineus is highly prevalent in rural regions of Western Siberia, causing severe liver and bile duct maladies. Praziquantel administered as a three-dose regimen is the only drug used to treat O. felineus-infected individuals. A simpler single-dose treatment might serve as an alternative. The aim of this study was to compare the pharmacokinetic (PK) properties of single, ascending doses of praziquantel compared to multiple dosing in patients infected with O. felineus to contribute to updated treatment guidelines. Dried blood spots (DBSs) of 110 adults were collected at 11 time points post-drug administration at single oral doses of 20, 40, and 60 mg/kg, as well as 3× 20 mg/kg (4 h dosing interval). DBS samples were analyzed using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method, and PK parameters were obtained for R-, S-, and R-trans-4-OH-praziquantel employing noncompartmental analysis. We observed the highest drug exposure for all analytes when the triple-dose scheme was used; area under the concentration-time curve from 0 to 24 h (AUC0-24) values of 8.04, 27.75, and 36.38 μg/mL·h were obtained, respectively. Maximal plasma concentrations (Cmax) values of 1.72, 4.89, and 2.69 μg/mL were calculated for R-, S-, and R-trans-4-OH-praziquantel, respectively, when patients were given a single 60-mg/kg dose, and they peaked at 1.5 and 2 h for the enantiomers and at 3 h for the metabolite. The herein-generated PK data, together with results that will be obtained from the integrated efficacy study, lay the groundwork for a possibly optimized treatment scheme for O. felineus-infected patients.

Entities:  

Keywords:  LC-MS/MS; Opisthorchis felineus; anthelmintic; dried blood spots; opisthorchiasis; pharmacokinetics; praziquantel

Mesh:

Substances:

Year:  2022        PMID: 36094183      PMCID: PMC9578388          DOI: 10.1128/aac.00526-22

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.938


  32 in total

1.  [An analysis of 4 strategies for the praziquantel treatment of persons infested with Opisthorchis felineus under conditions excluding reinfestation].

Authors:  A M Bronshteĭn; N N Ozeretskovskaia; E Ia Panteleeva; G L Pliushcheva; G A Gitsu
Journal:  Med Parazitol (Mosk)       Date:  1988 Sep-Oct

Review 2.  Altered CYP expression and function in response to dietary factors: potential roles in disease pathogenesis.

Authors:  Michael Murray
Journal:  Curr Drug Metab       Date:  2006-01       Impact factor: 3.731

3.  Efficacy and Safety of Praziquantel Against Light Infections of Opisthorchis viverrini: A Randomized Parallel Single-Blind Dose-Ranging Trial.

Authors:  Somphou Sayasone; Isabel Meister; Jason R Andrews; Peter Odermatt; Youthanavanh Vonghachack; Syda Xayavong; Kanpaseuth Senggnam; Khampheng Phongluxa; Jan Hattendorf; Isaac I Bogoch; Jennifer Keiser
Journal:  Clin Infect Dis       Date:  2017-02-15       Impact factor: 9.079

Review 4.  Opisthorchis felineus, an emerging infection in Italy and its implication for the European Union.

Authors:  Edoardo Pozio; Orlando Armignacco; Fabrizio Ferri; Maria Angeles Gomez Morales
Journal:  Acta Trop       Date:  2013-01-18       Impact factor: 3.112

Review 5.  Gender differences in the treatment of HIV infection.

Authors:  Marco Floridia; Marina Giuliano; Lucia Palmisano; Stefano Vella
Journal:  Pharmacol Res       Date:  2008-07-30       Impact factor: 7.658

6.  Clinical and pharmacokinetic study of praziquantel in Egyptian schistosomiasis patients with and without liver cell failure.

Authors:  M A el Guiniady; M A el Touny; M A Abdel-Bary; S A Abdel-Fatah; A Metwally
Journal:  Am J Trop Med Hyg       Date:  1994-12       Impact factor: 2.345

7.  Pharmacokinetics of Praziquantel in Schistosoma mansoni- and Schistosoma haematobium-Infected School- and Preschool-Aged Children.

Authors:  Jana Kovač; Isabel Meister; Anna Neodo; Gordana Panic; Jean T Coulibaly; Christine Falcoz; Jennifer Keiser
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

8.  Opisthorchis felineus infection, risks, and morbidity in rural Western Siberia, Russian Federation.

Authors:  Olga S Fedorova; Marina M Fedotova; Olga I Zvonareva; Sofia V Mazeina; Yulia V Kovshirina; Tatiana S Sokolova; Ekaterina A Golovach; Anna E Kovshirina; Uliana V Konovalova; Ivan L Kolomeets; Sergey S Gutor; Vyacheslav A Petrov; Jan Hattendorf; Ludmila M Ogorodova; Peter Odermatt
Journal:  PLoS Negl Trop Dis       Date:  2020-06-29

9.  Extrapolation of praziquantel pharmacokinetics to a pediatric population: a cautionary tale.

Authors:  Peter L Bonate; Tianli Wang; Paul Passier; Wilhelmina Bagchus; Howard Burt; Christian Lüpfert; Nada Abla; Jana Kovac; Jennifer Keiser
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-09-14       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.